What makes ten23 different from other CDMO companies?

The Company’s Mission: People, Patients and Planet

From its inception in 2021, ten23 has prioritized environmental responsibility, patient well-being and people’s sense of purpose at work. Demonstrating this commitment, our CEO Hanns-Christian Mahler proactively purchased 10 tons of plastic credits with SevenCleanSeas to offset anticipated waste from sterile drug production, even before operations commenced. This bold move underscores our company's dedication to integrating sustainability into its core operations.

The company’s Purpose: Design. Formulate. Deliver. Integrated Services for Complex Sterile Medicines

Recognizing the growing demand for sterile pharmaceuticals, the company strategically acquired a sterile fill & finish company in Switzerland shortly after its launch. This acquisition expanded the company's capabilities to offer comprehensive development and manufacturing services (fill&finish) for sterile medicines. By considering critical factors such as drug administration , delivery device selection, formulation stability and viscosity, and needle dimensions from the outset, ten23 health ensures that products are designed with the end-user and patient in mind. The company has achieved ISO9001 certification for its Basel laboratory and operates a GMP-certified sterile production facility in Visp.

Pioneering Sustainability in Pharma

We embed sustainability into every facet of our operations. Emphasizing immediate action over distant pledges, our Team has implemented sustainable practices such as installing LED lighting, utilizing water-saving fixtures, and promoting comprehensive recycling programs. Notably, the company is exploring the use of biodegradable disposables in collaboration with industry partners, aiming to reduce reliance on single-use plastics in aseptic environments. ten23 is also using AI, in collaboration with Elio, to improve sustainability in pharma along its value chains.

B Corp Certification: A Testament to Impact

In September 2024, ten23 health became the first biotech and sterile drug product CDMO to achieve B Corporation (B Corp) certification. This prestigious designation reflects the company's adherence to strict standards of social and environmental performance, accountability, and transparency. By meeting these high benchmarks, the brand "ten23" demonstrates its dedication to using business as a force for good, positively impacting employees, communities, and the environment.

Through its unwavering focus on sustainability, patient-centric development, and progressive organizational practices, the enterprise sets a new standard in the CDMO industry, exemplifying how companies can successfully balance business objectives with social and environmental responsibility.

Innovative Organizational Design

Departing from traditional hierarchical structures, we employ a role-based system that empowers employees to leverage their strengths and pursue their interests. This approach fosters a culture of trust and motivation, enabling team members to take on diverse roles that align with their passions and expertise. For instance, a technician with an interest in diversity initiatives became the company's LGBTQ officer while continuing her laboratory work, exemplifying the flexibility and inclusivity of ten23 health's organizational model.

By seamlessly integrating sustainability, patient-centric innovation, and a progressive organizational structure, we are redefining what it means to be a modern CDMO. With a steadfast commitment to environmental responsibility, high-quality sterile drug development, and an empowering workplace culture, the company continues to set new benchmarks in the industry. As our firm grows, it remains dedicated to Design, Formulate and Deliver complex sterile medicines, while fostering a positive impact on People, Patients, and the Planet.